Catalent, the American company specialised in advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced the acquisition of Micron Technologies, a leading global provider of particle size engineering technologies.

The operation represents an important advance, according to Catalent, in its strategy to provide the best drug delivery technologies, with the goal to partner with more pharmaceutical innovators at the earliest stages of the drug development process.

Micron Technologies developed a versatile portfolio of particle size reduction, micronization and milling technologies used to overcome bioavailability, stability and manufacturability challenges.

The deal follows the acquisition of Redwood Bioscience, with its Antibody-Drug Conjugate (ADC) technology platform, in October 2014.